TNXPHIGH SIGNALREGULATORY10-K

TNXP achieved FDA approval for TONMYA (formerly TNX-102 SL) for fibromyalgia treatment, marking its first internally developed commercial product.

This represents a transformative milestone for the biopharmaceutical company, transitioning from a pure development-stage entity to a commercial organization with an approved product. The FDA approval validates years of clinical development and provides a foundation for revenue generation, though the company will now face the commercial execution challenge of market penetration and sales growth.

Comparing 2026-03-12 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

The balance sheet shows substantial strengthening with current assets growing 92% to $229M and stockholders' equity expanding 76% to $245M, likely reflecting capital raises to fund commercialization efforts. Revenue grew modestly to $13.1M while operating cash outflows increased meaningfully to $99.8M, indicating higher commercial and operational spending as the company launches its newly approved product. The overall financial position appears robust for supporting the commercial launch, though the increased cash burn reflects the investment phase of bringing TONMYA to market.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+92.3%
$119.0M→$228.9M

Current assets grew 92.3% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+75.7%
$139.6M→$245.2M

Equity base grew 75.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+70.3%
$3.7M→$6.3M

Receivables surged 70.3% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Assets
Balance Sheet
+70.2%
$162.9M→$277.2M

Asset base grew 70.2% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+68.4%
$18.3M→$30.8M

Current liabilities surged 68.4% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-63.9%
-$60.9M→-$99.8M

Operating cash flow fell 63.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Inventory
Balance Sheet
-38.4%
$13.6M→$8.4M

Inventory drawn down 38.4% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Liabilities
Balance Sheet
+37.2%
$23.3M→$32.0M

Liabilities grew 37.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
+29.8%
$10.1M→$13.1M

Revenue growing 29.8% — solid top-line momentum, watch margins for quality of growth.

Total Debt
Balance Sheet
-21.4%
$11.0M→$8.7M

Debt reduced 21.4% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-18
ADDED
As of March 11, 2026, there were 13,405,401 shares of registrant s common stock outstanding.
3 Business Overview We ( Tonix or the Company ) are a fully-integrated biopharmaceutical company commercializing and developing innovative therapies for central nervous system ( CNS ) disorders, immunology, infectious diseases, and rare diseases.
Our portfolio consists of commercial, development and discovery-stage programs.
Food and Drug Administration ( FDA ) for TONMYA for the treatment of fibromyalgia in adults.
TONMYA is our first internally developed product to receive FDA approval.
+7 more — sign up free →
REMOVED
Such determination should not be deemed an admission that such directors, officers, or 5 percent beneficial owners are, in fact, affiliates of the registrant.
As of March 17, 2025, there were 6,434,881 shares of registrant s common stock outstanding.
Forward-looking statements include, but are not necessarily limited to, those relating to: Our prospects are dependent on the success of TNX 102-SL for the management of Fibromyalgia ( FM ) and progressing our pipeline through development stages.
To the extent regulatory approval of TNX-102 SL is delayed or not granted or, if approved, TNX-102 SL is not commercially successful, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.
Business Overview Tonix Pharmaceuticals ( Tonix or the Company ) is a fully-integrated biopharmaceutical company developing and commercializing therapeutics to treat, and vaccines to prevent, disease and alleviate suffering.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →